title: [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
abstract: The prevention of cancer treatment-induced bone loss in patients with prostate cancer due to gonadotropin-releasing hormone (GnRH)-agonist, GnRH-antagonist and orchidectomi therapy has a high priority. We present an algorithm for the prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer.
authors: Kardiologisk-endokrinologisk Afdeling H, Hillerød Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark. piei@hih.regionh.dk
authors: Pia A
authors: PA
authors: Eiken
authors: Bente L
authors: BL
authors: Langdahl
authors: Frederik L
authors: FL
authors: Eiken
authors: Steen
authors: S
authors: Walter
authors: Mads Hvid
authors: MH
authors: Poulsen
authors: Bo
authors: B
authors: Abrahamsen
mesh_terms: D015502:Absorptiometry, Photon; D000726:Androgen Antagonists / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects; D010024:Osteoporosis / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab